Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Menorrhagia
Interventions: Oral tranexamic acid, Oral Contraceptive Pills; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 21 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain, Pain, Opioid Withdrawal (Disorder), Opioid Use Disorder
Interventions: Cebranopadol, Placebo; Drug
Lead sponsor: Adneuris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: North Canton, Ohio • Houston, Texas

Conditions: Pain
Interventions: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%), Placebo Peel; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 3
States / cities: Englewood, Colorado • Nashville, Tennessee • Bryan, Texas

Conditions: Diabetic Peripheral Neuropathy
Interventions: NYX-2925, Placebo; Drug
Lead sponsor: Aptinyx; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Phoenix, Arizona • Anaheim, California • Fresno, California + 29 more

Conditions: Geographic Atrophy Secondary to Age-Related Macular Degeneration
Interventions: RO7965032, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 5
States / cities: Walnut Creek, California • Winston-Salem, North Carolina • Erie, Pennsylvania + 2 more

Conditions: Infections
Interventions: E-101 Solution 300 GU/ml, Saline solution; Drug
Lead sponsor: Excited States, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 34
States / cities: Mobile, Alabama • Los Angeles, California • Stanford, California + 29 more

Conditions: Narcolepsy
Interventions: SUVN-G3031, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more

Conditions: Dysbiosis, Endotoxemia, Metabolic Syndrome, Inflammation
Interventions: Green Tea Extract, Placebo; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Neonatal Opioid Withdrawal Syndrome
Interventions: CHF6563, Morphine, CHF6563 matched placebo, Morphine matched placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: Up to 7 Days
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Las Vegas, Nevada • Philadelphia, Pennsylvania

Conditions: Amblyopia, Strabismus
Interventions: Binocular Treatment, Sham Binocular Treatment; Procedure
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Differentiated Thyroid Cancer
Interventions: Cabozantinib, Placebo; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 16 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 31
States / cities: Newport Beach, California • Sacramento, California • San Francisco, California + 27 more

Conditions: Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Interventions: BXQ-350, Placebo; Drug · Other
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee

Conditions: Tuberculosis
Interventions: BCG strain Connaught, BCG strain Danish, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Plaque-type Psoriasis
Interventions: CJM112, Secukinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Anniston, Alabama • Anaheim, California • Encino, California + 14 more

Conditions: Metabolic Syndrome
Interventions: intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test; Procedure · Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Neurofibroma, Plexiform, Neurofibromatosis Type I
Interventions: tipifarnib, placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 25 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more

Conditions: Overweight, Obesity and Other Hyperalimentation (E65-E68)
Interventions: Berry fruit powder OR nutritional ketosis, Placebo powder OR higher carbohydrate; Dietary Supplement
Lead sponsor: University of Cincinnati; Other
Eligibility: 50 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Obstructive Sleep Apnea
Interventions: Acetazolamide, Placebo, Continuous Positive Airway Pressure; Drug · Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Post-surgical Dental Pain
Interventions: PF-04531083, Placebo, Ibuprofen; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Atopic Dermatitis
Interventions: Oral EP262, Placebo; Drug
Lead sponsor: Escient Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Miami Lakes, Florida • Plainfield, Indiana + 6 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Birmingham, Alabama • Jasper, Alabama • Torrance, California + 8 more

Conditions: Prostate Cancer Metastatic
Interventions: Veru-944, Placebo; Drug
Lead sponsor: Veru Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Glendale, Arizona • Los Angeles, California • San Bernardino, California + 20 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: baclofen/amitriptyline/ketamine gel, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 165
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 104 more

Conditions: Healthy
Interventions: Placebo, Nitrate supplement with caffeine; Dietary Supplement
Lead sponsor: University of Texas at Austin; Other
Eligibility: 21 Years to 49 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study

A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Skin Filler Injection in the Face

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome

CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

Binocular Treatment of Amblyopia Before and After Strabismus Surgery

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

BCG Vaccination Delivered Intradermally, Orally and by Combined Routes

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Insulin Sensitivity in Men With the Metabolic Syndrome

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Early Intervention in Cognitive Aging

Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health

Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Effects of Neo40(TM) With Caffeine on Cycling Time Trial Performance